Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

April 22, 2025
Publication of Annual Report 2024 PRESS RELEASE REGULATED INFORMATION 22 April 2025, 18:00 pm CEST Ghent, Belgium – 22 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today invites the holders of securities...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES